As a notorious night owl, it was already very early in the morning of October 5 when Karl Deisseroth, M.D., Ph.D., finally ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...
What does it mean to be a Fierce 15 biotech in 2026? With this year’s list unveiled, the Fierce Biotech team gets together to ...
Endeavor BioMedicines has solidified its potential threat to Big Pharma with a phase 2b readout suggesting its Hedgehog inhibitor could become the first drug to reduce lung fibrosis while increasing ...
Iambic Therapeutics is aiming for a $135 million IPO in net proceeds as the AI biotech looks to fund the clinical development ...
To a passerby, the glass-fronted 10 Prospect building rising above the low-slung restaurant and retail space of Somerville's ...
Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset
Japan’s Ono Pharmaceutical is paying $80 million upfront for the regional rights to a trio of Biohaven’s IgG degraders led by ...
A phase 2 celiac disease trial of argenx’s FB102 has hit its primary endpoint, delivering a boost to a drug candidate that ...
Cadrenal Therapeutics, a heart-focused biotech that recently reached an agreement with the FDA on the design of a pivotal ...
The U.S. Department of Health and Human Services announced the launching of a new program aimed to remove barriers that slow clinical development and transform how clinical trials are designed and ...
TCGX is expanding its operations to Asia in connection with the fund, opening offices in Shanghai and Hong Kong. Dandan Dong, ...
Atsena expects to complete enrollment in the third part of the Lighthouse study next year. (den-belitsky/iStock/ Plus) Atsena Therapeutics has reported evidence of efficacy in a clinical trial of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results